Martin Kolb, MD, PhD, professor of medicine at McMaster University, previews key topics to be presented at this year's European Respiratory Society (ERS) Congress.
The European Respiratory Society (ERS) Congress 2024 will address various aspects of applying artificial intelligence into respiratory medicine, and there will be many exciting presentations on this topic for attendees, says Martin Kolb, MD, PhD, professor of medicine at McMaster University.
This transcript was lightly edited.
Transcript
What are you most excited for at this year's ERS Congress?
The ERS Congress is one of the largest, if not the largest, international gatherings of respiratory experts, and it is in Vienna this time. It will cater to a very broad audience, from industry and academia, [as well as] learners and teachers. It’s a prime gathering.
There are a number of very important and hopefully informative sessions on clinical trials, and why some of the recent clinical trials have failed. There are topics on pollution, environmental, and occupational exposures for people who develop idiopathic pulmonary fibrosis, which may make this disease less idiopathic. There will be sessions focused on the relationship between exposures and interstitial lung disease. Of course, a big topic at the ERS Congress is artificial intelligence.
As many of you will know, artificial intelligence is something that you read [about] everywhere nowadays, in every aspect of life, and it's entering respiratory medicine too. I still don't know how to take artificial intelligence and how to apply it to practice. It certainly is a wonderful research tool and will probably be important for guidelines going forward and making prognostic statements about diseases or a cohort of disease patients.
I don't see yet much [of a] role for an individual. I don't think it's something that will enter the true clinical practice other than indirectly, through big picture statements. But it's a big topic, so it will be shown and showcased in interstitial lung disease, infectious disease, and in other disease areas. So, those are all things that are certainly exciting.
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More